MERS-CoV Nucleocapsid Protein (His Tag)
Cat: 40068-V08B
MERS-CoV Nucleocapsid Protein (His Tag): Product Information
Purity
> 90 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the MERS-CoV Nucleoprotein (AFS88943.1) (Met1-Asp413) was fused with a polyhistidine tag at the C-terminus.
Accession#
Expressed Host
Baculovirus-Insect Cells
Species
MERS-CoV
Predicted N Terminal
Met 1
Molecule Mass
The recombinant Nucleoprotein MERS-CoV comprises 424 amino acids and has a predicted molecular mass of 46.51 kDa.
Formulation
Lyophilized from sterile 20mM Tris, 500mM NaCl, 10% gly, pH 8.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
MERS-CoV Nucleocapsid Protein (His Tag): Images
MERS-CoV Nucleocapsid Protein (His Tag): Synonyms
coronavirus NP Protein, MERS-CoV; coronavirus Nucleocapsid Protein, MERS-CoV; coronavirus Nucleoprotein Protein, MERS-CoV; cov np Protein, MERS-CoV; ncov NP Protein, MERS-CoV; novel coronavirus Nucleoprotein Protein, MERS-CoV; NP Protein, MERS-CoV; Nucleocapsid Protein, MERS-CoV; Nucleoprotein Protein, MERS-CoV
Coronavirus Nucleocapsid Background Information
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
References
- 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12.
- Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6.
- Li W. et al., 2005, Science. 309 (5742): 1864-8.
SARS-CoV-2 Coronavirus Nucleocapsid Proteins
HCoV-NL63 Coronavirus Nucleocapsid Proteins
HCoV-OC43 Coronavirus Nucleocapsid Proteins
HCoV-229E Coronavirus Nucleocapsid Proteins
SARS Coronavirus Nucleocapsid Proteins
HCoV-HKU1 Coronavirus Nucleocapsid Proteins
-
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen MicroarrayAuthorDe Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;Year2020JournalBioRxiv
-
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayAuthorKhan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;Year2020JournalBioRxiv
If you couldn't find the specific citation, you can:
